Ostatné · RVMD
Revolution Medicines, Inc.
Fundamenty firmy Healthcare · Biotechnology · United States
Hodnotenie 0–10, vypočítané z údajov firmy
Analytici 22 hodnotení
silný nákup
- Najnižší cieľ
- 179,00
- Priemerný cieľ
- 257,47
- Najvyšší cieľ
- 320,00
- Potenciál
- +25,2 %
Odhad zisku na akciu (EPS)
| Obdobie | Odhad | Rozpätie | Pred rokom | Rast |
|---|---|---|---|---|
| tento štvrťrok | -2,39 | -3,26–-2,07 | -1,61 | −48,5 % |
| budúci štvrťrok | -2,01 | -3,68–-0,41 | -1,86 | −8,1 % |
| tento rok | -9,65 | -12,35–-8,00 | -5,95 | −62,2 % |
| budúci rok | -5,83 | -9,35–-1,92 | -9,65 | +39,6 % |
Odhad tržieb
| Obdobie | Odhad | Pred rokom | Rast |
|---|---|---|---|
| tento štvrťrok | 23,0 mil. | – | +0,0 % |
| budúci štvrťrok | 148,2 mil. | – | +0,0 % |
| tento rok | 181,6 mil. | – | +0,0 % |
| budúci rok | 1,2 mld. | 181,6 mil. | +581,7 % |
Nákupy a predaje manažérov insider
| Kto | Čo | Hodnota | Dátum |
|---|---|---|---|
| Sandler Alan B.Officer | uplatnenie opcií | 353 040 | 29.09. |
| Sandler Alan B.Officer | predaj | 1,3 mil. | 29.09. |
| Mancini AnthonyOfficer | uplatnenie opcií | 104 928 | 25.09. |
| Cislini Jeffrey ToddGeneral Counsel | predaj | 158 600 | 25.09. |
| Mancini AnthonyOfficer | predaj | 743 285 | 25.09. |
| Anderson Elizabeth MDirector | uplatnenie opcií | 5 678 | 22.09. |
| Anderson Elizabeth MDirector | predaj | 2,0 mil. | 22.09. |
| Mancini AnthonyOfficer | predaj | 347 402 | 18.09. |
| Kelsey Stephen MichaelOfficer | uplatnenie opcií | 3,9 mil. | 11.09. |
| Kelsey Stephen MichaelOfficer | predaj | 18,7 mil. | 11.09. |
| Mancini AnthonyOfficer | uplatnenie opcií | 314 784 | 10.09. |
| Mancini AnthonyOfficer | predaj | 3,2 mil. | 10.09. |
Kto vlastní akcie
Slávni investori: Stanley Druckenmiller · 1.7 %
Blackrock Inc.6,39 %
Farallon Capital Management LLC6,32 %
FMR, LLC5,69 %
Baker Bros. Advisors, LP5,34 %
Jupiter Topco LLC5,01 %
Darwin Global Management, Ltd.4,96 %
Vanguard Capital Management LLC4,24 %
Vanguard Portfolio Management LLC3,87 %
O firme (popis z Yahoo Finance, anglicky)
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Názor AI
Krátke zhodnotenie trendu, správ a blížiacich sa udalostí.
Technické signály
- Rastový trend – Kurz nad SMA50 aj SMA200, SMA50 nad SMA200
Odporúčania
K tomuto aktívu zatiaľ nemáme odporúčanie.
Predikcie
Žiadne predikcie.
Súvisiace správy
Žiadne správy so značkou RVMD.